0001367644-23-000071.txt : 20230306 0001367644-23-000071.hdr.sgml : 20230306 20230306193708 ACCESSION NUMBER: 0001367644-23-000071 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230302 FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kramer Robert CENTRAL INDEX KEY: 0001380956 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 23710620 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 wf-form4_167814941740129.xml FORM 4 X0306 4 2023-03-02 0 0001367644 Emergent BioSolutions Inc. EBS 0001380956 Kramer Robert 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 1 1 0 0 President and CEO Common Stock 2023-03-02 4 A 0 19231 0 A 255289 D Common Stock 2023-03-02 4 A 0 38462 0 A 293751 D Employee Stock Options (Right to Buy) 12.06 2023-03-02 4 A 0 38462 0 A 2030-03-01 Common Stock 38462.0 258182 D Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Represents the corrected number of securities owned due to a computational error on prior Form-4. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Vests in three equal installments beginning on the day prior to the anniversary date of the grant. /s/ Jennifer Lynn Fox, Attorney-in-fact 2023-03-06